From Human Genetics to Therapy: Targeting Alcohol and Steatotic Liver Disease via the FGF21 Live

The research landscape of steatotic liver disease (SLD) is undergoing a profound transformation. The nomenclature redefinition has highlighted as major drivers of SLD metabolic dysfunction and insulin resistance, harmful alcohol intake, environmental exposures and genetic causes [1]. While the two first drugs, namely semaglutide and resmetirom, have been approved to target the systemic and liver specific metabolic components in patients with metabolic dysfunction associated steatotic liver disease (MASLD) [2], no therapy is yet available to reduce harmful alcohol intake.